New ASPS Clinical Trial: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

New clinical trial for ASPS is expected to open on March 2016.

Study number: NCT02636725

This is a phase II clinical trial that combines treatment with Axitinib and Pembrolizumab in patients with advanced Alveolar Soft Part Sarcoma (ASPS) and other soft tissue sarcomas.

Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.

Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is an antibody used in cancer immunotherapy to target the programmed cell death 1 (PD-1) receptor.

Patients will be treated with twice daily dosing of axitinib alone for the first 7 days, followed by concurrent axitinib administered twice daily at 5 mg orally (PO), plus intravenous administration of pembrolizumab every 21 days. Patients will be assessed every three weeks for toxicity.

The study will include up to 30 patients

Contact information:

Breelyn Wilky, MD, University of Miami
Phone: 305-243-1287

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)